Mucosal healing in pediatric Crohn's disease: Pro/con balance

Inflammatory Bowel Diseases

Volumn 10, Issue 4, 2004, Pages 484-

  Escher, Johanna C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; INFLIXIMAB; MERCAPTOPURINE; STEROID;

ABSCESS; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; ENDOSCOPY; ENTERIC FEEDING; GROUPS BY AGE; GROWTH RATE; HEALING; HUMAN; INTESTINAL FIBROSIS; INTESTINE FISTULA; INTESTINE MUCOSA; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; VALIDATION PROCESS;

CHILD; CLINICAL TRIALS; CROHN DISEASE; DRUG RESISTANCE; ENDPOINT DETERMINATION; HUMANS; INTESTINAL MUCOSA; TREATMENT OUTCOME;

EID: 3543057650     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200407000-00026     Document Type: Note

References (4)

1. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
2. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
3. Rutgeerts P, Van Assche G, Van Deventer S, et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohns disease. Gastroenterology. 2002;122:A618.
4. D'Haens G, Noman M, Baert F, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology. 2002;122:A100.